Stocks
By market cap · 24 stocks
- 1
ACADAcadia PharmaceuticalsNUPLAZID and DAYBUE neuroscience medicines$4.52B+0.04% - 2
DNLIDenali TherapeuticsDeveloper of blood-brain-barrier-crossing medicines$3.25B+5.52% - 3
PRTAProthenaPartnered protein-dysregulation pipeline developer$445.5M+5.76% - 4
VNDAVanda PharmaceuticalsFanapt and HETLIOZ specialty biopharma$310.0M+1.07% - 5
IKTInhibikase TherapeuticsPAH-focused kinase drug developer$290.5M+5.45% - 6
ACIUAC ImmuneDeveloper of neurodegeneration therapies and diagnostics$270.2M+3.20% - 7
AVXLAnavex Life SciencesDeveloper of oral therapies for brain disorders$222.4M+2.71% - 8
ALECAlectorABC-enabled neurodegeneration drug developer$214.3M+3.63% - 9
ABOSAcumen PharmaceuticalsDeveloper of an oligomer-targeting Alzheimer’s antibody$187.1M+2.12% - 10
VYGRVoyager TherapeuticsTRACER-enabled neurogenetic medicines developer$186.1M+2.11% - 11
NERVMinerva NeurosciencesSchizophrenia drug developer centered on roluperidone$171.7M+3.94% - 12
ACOGAlpha CognitionZUNVEYL maker for Alzheimer’s care$139.3M−0.84% - 13
CGTXCognition TherapeuticsZervimesine developer for Lewy body dementia psychosis$89.5M−1.34% - 14
ANVSAnnovis BioDeveloper of buntanetap for neurodegenerative disease$50.6M+5.88% - 15
TAOXTAO SynergiesBittensor TAO treasury and staking vehicle$35.9M−5.62% - 16
FLNAFilana TherapeuticsDeveloper of simufilam for TSC-related epilepsy$35.7M+39.28% - 17
GRMLGreenland MinesSkaergaard mineral explorer with an ALS biotech program$28.4M+49.93% - 18
LONALeonaBioDeveloper of breast cancer and ALS therapies$25.0M−5.53% - 19
CRVOCervoMedDeveloper of neflamapimod for brain disorders$22.3M+5.39% - 20
PMNProMIS NeurosciencesEpiSelect antibody developer for neurodegenerative diseases$17.8M+1.21% - 21
CYCNCyclerion TherapeuticsSuspended depression system and sGC licensing portfolio$15.7M0.00% - 22
ALZNAlzamend NeuroAL001 and ALZN002 neuroscience drug developer$7.4M−0.26% - 23
ARTLArtelo BiosciencesClinical developer of lipid-signaling drug candidates$1.6M+1.83% - 24
JUNSJupiter NeurosciencesJOTROL-based CNS drug developer and Nugevia supplement seller$1.4M+3.48%